TNDM
What one share of Tandem Diabetes Care holds
Surgical and Medical Instruments and Apparatus
Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology, specializing in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management. We serve nearly 500,000 people living with diabetes in more than 25 countries worldwide.
Tandem Diabetes Care’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $15.25 |
|---|---|
| Profit | −$0.93 |
| Capex (buildings and equipment) | $0.31 |
| Free cash flow | −$0.39 |
| Cash and investments | $0.90 |
| Debt | $8.67 |
| Book value | $1.88 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $27.56 | −$27.30 | $2.92 | −$22.93 | — | −$1.91 |
| 2017 | $18.95 | −$12.86 | $1.01 | −$12.66 | — | −$2.88 |
| 2018 | $3.82 | −$2.55 | $0.06 | −$0.23 | — | $2.28 |
| 2019 | $6.19 | −$0.42 | $0.33 | $0.38 | — | $3.28 |
| 2020 | $8.18 | −$0.56 | $0.45 | −$0.04 | — | $5.88 |
| 2021 | $10.92 | $0.24 | $0.22 | $1.51 | — | $6.79 |
| 2022 | $12.49 | −$1.47 | $0.53 | $0.26 | — | $6.82 |
| 2023 | $11.51 | −$3.43 | $0.41 | −$0.90 | — | $4.78 |
| 2024 | $14.37 | −$1.47 | $0.29 | $0.08 | — | $3.97 |
| 2025 | $15.08 | −$3.04 | $0.30 | −$0.44 | — | $2.27 |